DCGI approves Johnson &Johnson’ single-dose vaccine for adolescents aged 12-17 years

The Johnson & Johnson single-dose vaccine for children aged 12 to 17 years in the country has been approved by the Drug Controller General of India (DCGI). American pharma giant Johnson & Johnson has previously applied to the Central Drugs Standard Control Organization (CDSCO) in India for permission to conduct clinical trials of a single-shot vaccine against Covid-19 in adolescents aged 12-17 years.

The single-shot Covid vaccine developed by Johnson & Johnson has shown 85 percent effectiveness in preventing Covid in the third stage of trials.  With this, India approved the Johnson & Johnson single dose vaccine for emergency use.

The Union Health Minister said the vaccine would help control the coronavirus in the country. The Drugs Controller of India has been approved for emergency use, a senior Union Health Ministry official said. Johnson & Johnson India said in a statement that the Covid-19 vaccine is an important step towards helping end the corona epidemic.

“We are pleased that the Government of India has issued the Johnson & Johnson Covid-19 Single-Dose Vaccine Emergency Authorization Authority to prevent Covid under 18 years of age,” a company spokesman said.

Related Articles

- Advertisement -

Latest Articles